## Stephan Günther

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5535913/publications.pdf

Version: 2024-02-01

207 papers

21,674 citations

14655 66 h-index 138 g-index

218 all docs

218 docs citations

times ranked

218

21698 citing authors

#	Article	IF	CITATIONS
1	Identification of a Novel Coronavirus in Patients with Severe Acute Respiratory Syndrome. New England Journal of Medicine, 2003, 348, 1967-1976.	27.0	3,971
2	Emergence of Zaire Ebola Virus Disease in Guinea. New England Journal of Medicine, 2014, 371, 1418-1425.	27.0	1,193
3	Real-time, portable genome sequencing for Ebola surveillance. Nature, 2016, 530, 228-232.	27.8	1,179
4	Efficacy and effectiveness of an rVSV-vectored vaccine in preventing Ebola virus disease: final results from the Guinea ring vaccination, open-label, cluster-randomised trial (Ebola $\tilde{A}$ ‡a Suffit!). Lancet, The, 2017, 389, 505-518.	13.7	837
5	Efficacy and effectiveness of an rVSV-vectored vaccine expressing Ebola surface glycoprotein: interim results from the Guinea ring vaccination cluster-randomised trial. Lancet, The, 2015, 386, 857-866.	13.7	715
6	Rapid Detection and Quantification of RNA of Ebola and Marburg Viruses, Lassa Virus, Crimean-Congo Hemorrhagic Fever Virus, Rift Valley Fever Virus, Dengue Virus, and Yellow Fever Virus by Real-Time Reverse Transcription-PCR. Journal of Clinical Microbiology, 2002, 40, 2323-2330.	3.9	527
7	A novel method for efficient amplification of whole hepatitis B virus genomes permits rapid functional analysis and reveals deletion mutants in immunosuppressed patients. Journal of Virology, 1995, 69, 5437-5444.	3.4	464
8	Successful treatment of advanced Ebola virus infection with T-705 (favipiravir) in a small animal model. Antiviral Research, 2014, 105, 17-21.	4.1	428
9	Experimental Treatment with Favipiravir for Ebola Virus Disease (the JIKI Trial): A Historically Controlled, Single-Arm Proof-of-Concept Trial in Guinea. PLoS Medicine, 2016, 13, e1001967.	8.4	382
10	Virus genomes reveal factors that spread and sustained the Ebola epidemic. Nature, 2017, 544, 309-315.	27.8	346
11	Ebola virus disease. Lancet, The, 2019, 393, 936-948.	13.7	305
12	Taxonomy of the order Bunyavirales: update 2019. Archives of Virology, 2019, 164, 1949-1965.	2.1	285
13	A Case of Severe Ebola Virus Infection Complicated by Gram-Negative Septicemia. New England Journal of Medicine, 2014, 371, 2394-2401.	27.0	270
14	X-ray screening identifies active site and allosteric inhibitors of SARS-CoV-2 main protease. Science, 2021, 372, 642-646.	12.6	240
15	Clinical Sequencing Uncovers Origins and Evolution of Lassa Virus. Cell, 2015, 162, 738-750.	28.9	230
16	Naturally Occurring Variants of Hepatitis B Virus. Advances in Virus Research, 1999, 52, 25-137.	2.1	222
17	Resurgence of Ebola Virus Disease in Guinea Linked to a Survivor With Virus Persistence in Seminal Fluid for More Than 500 Days. Clinical Infectious Diseases, 2016, 63, 1353-1356.	5.8	201
18	Metagenomic sequencing at the epicenter of the Nigeria 2018 Lassa fever outbreak. Science, 2019, 363, 74-77.	12.6	201

#	Article	IF	CITATIONS
19	Cinanserin Is an Inhibitor of the 3C-Like Proteinase of Severe Acute Respiratory Syndrome Coronavirus and Strongly Reduces Virus Replication In Vitro. Journal of Virology, 2005, 79, 7095-7103.	3.4	185
20	2020 taxonomic update for phylum Negarnaviricota (Riboviria: Orthornavirae), including the large orders Bunyavirales and Mononegavirales. Archives of Virology, 2020, 165, 3023-3072.	2.1	184
21	Lassa Virus. Critical Reviews in Clinical Laboratory Sciences, 2004, 41, 339-390.	6.1	179
22	<i>Mastomys natalensi</i> s and Lassa Fever, West Africa. Emerging Infectious Diseases, 2006, 12, 1971-1974.	4.3	175
23	Unique human immune signature of Ebola virus disease in Guinea. Nature, 2016, 533, 100-104.	27.8	170
24	Imported Lassa Fever in Germany: Molecular Characterization of a New Lassa Virus Strain. Emerging Infectious Diseases, 2000, 6, 466-476.	4.3	168
25	Zika virus infections imported to Italy: Clinical, immunological and virological findings, and public health implications. Journal of Clinical Virology, 2015, 63, 32-35.	3.1	158
26	The N-Terminal Domain of the Arenavirus L Protein Is an RNA Endonuclease Essential in mRNA Transcription. PLoS Pathogens, 2010, 6, e1001038.	4.7	145
27	Cytokine kinetics of Zika virus-infected patients from acute to reconvalescent phase. Medical Microbiology and Immunology, 2016, 205, 269-273.	4.8	142
28	Imported Lassa Fever in Germany: Surveillance and Management of Contact Persons. Clinical Infectious Diseases, 2003, 36, 1254-1258.	<b>5.</b> 8	139
29	Management of Accidental Exposure to Ebola Virus in the Biosafety Level 4 Laboratory, Hamburg, Germany. Journal of Infectious Diseases, 2011, 204, S785-S790.	4.0	138
30	Evaluation of Antiviral Efficacy of Ribavirin, Arbidol, and T-705 (Favipiravir) in a Mouse Model for Crimean-Congo Hemorrhagic Fever. PLoS Neglected Tropical Diseases, 2014, 8, e2804.	3.0	138
31	Molecular diagnostics of viral hemorrhagic fevers. Antiviral Research, 2003, 57, 61-87.	4.1	135
32	Type, prevalence, and significance of core promoter/enhancer II mutations in hepatitis B viruses from immunosuppressed patients with severe liver disease. Journal of Virology, 1996, 70, 8318-8331.	3.4	134
33	Molecular Diagnostics for Lassa Fever at Irrua Specialist Teaching Hospital, Nigeria: Lessons Learnt from Two Years of Laboratory Operation. PLoS Neglected Tropical Diseases, 2012, 6, e1839.	3.0	131
34	New Hosts of The Lassa Virus. Scientific Reports, 2016, 6, 25280.	3.3	130
35	Reactivation of Hepatitis B Virus Replication Accompanied by Acute Hepatitis in Patients Receiving Highly Active Antiretroviral Therapy. Clinical Infectious Diseases, 2001, 32, 144-148.	5 <b>.</b> 8	127
36	Replicon System for Lassa Virus. Journal of Virology, 2004, 78, 13793-13803.	3.4	122

#	Article	IF	CITATIONS
37	Monitoring of clinical and laboratory data in two cases of imported Lassa fever. Microbes and Infection, 2002, 4, 43-50.	1.9	116
38	Heterogeneity and Common Features of Defective Hepatitis B Virus Genomes Derived from Spliced Pregenomic RNA. Virology, 1997, 238, 363-371.	2.4	115
39	Transcriptomic signatures differentiate survival from fatal outcomes in humans infected with Ebola virus. Genome Biology, 2017, 18, 4.	8.8	115
40	Taxonomy of the order Bunyavirales: second update 2018. Archives of Virology, 2019, 164, 927-941.	2.1	115
41	Resurgence of Ebola virus in 2021 in Guinea suggests a new paradigm for outbreaks. Nature, 2021, 597, 539-543.	27.8	113
42	Antiviral efficacy of favipiravir against Ebola virus: A translational study in cynomolgus macaques. PLoS Medicine, 2018, 15, e1002535.	8.4	108
43	RT-PCR assay for detection of Lassa virus and related Old World arenaviruses targeting the L gene. Transactions of the Royal Society of Tropical Medicine and Hygiene, 2007, 101, 1253-1264.	1.8	107
44	Rapid outbreak sequencing of Ebola virus in Sierra Leone identifies transmission chains linked to sporadic cases. Virus Evolution, 2016, 2, vew016.	4.9	105
45	Persistence and clearance of Ebola virus RNA from seminal fluid of Ebola virus disease survivors: a longitudinal analysis and modelling study. The Lancet Global Health, 2017, 5, e80-e88.	6.3	100
46	Clinical and laboratory predictors of Lassa fever outcome in a dedicated treatment facility in Nigeria: a retrospective, observational cohort study. Lancet Infectious Diseases, The, 2018, 18, 684-695.	9.1	100
47	Frequent and rapid emergence of mutated pre-C sequences in HBV from e-antigen positive carriers who seroconvert to anti-HBe during interferon treatment. Virology, 1992, 187, 271-279.	2.4	99
48	Hepatitis B virus genomes of patients with fulminant hepatitis do not share a specific mutation. Hepatology, 1996, 24, 300-306.	7.3	95
49	Efficacy of Favipiravir Alone and in Combination With Ribavirin in a Lethal, Immunocompetent Mouse Model of Lassa Fever. Journal of Infectious Diseases, 2016, 213, 934-938.	4.0	95
50	Wild-type levels of pregenomic RNA and replication but reduced pre-C RNA and e-antigen synthesis of hepatitis B virus with $C(1653)$ > T, $A(1762)$ > T and $G(1764)$ > A mutations in the core promoter Journal of General Virology, 1998, 79, 375-380.	2.9	95
51	Ribavirin for the treatment of Lassa fever: A systematic review and meta-analysis. International Journal of Infectious Diseases, 2019, 87, 15-20.	3.3	94
52	Sequence analysis of L RNA of Lassa virus. Virology, 2004, 318, 153-168.	2.4	92
53	Functional analysis of hepatitis B virus reactivating in hepatitis B surface antigen-negative individuals. Hepatology, 2005, 42, 93-103.	7.3	92
54	T Cell-Dependence of Lassa Fever Pathogenesis. PLoS Pathogens, 2010, 6, e1000836.	4.7	89

#	Article	IF	Citations
55	Lassa Fever Encephalopathy: Lassa Virus in Cerebrospinal Fluid but Not in Serum. Journal of Infectious Diseases, 2001, 184, 345-349.	4.0	86
56	Improved Detection of Lassa Virus by Reverse Transcription-PCR Targeting the 5′ Region of S RNA. Journal of Clinical Microbiology, 2010, 48, 2009-2013.	3.9	84
57	Comparative Structural and Functional Analysis of Bunyavirus and Arenavirus Cap-Snatching Endonucleases. PLoS Pathogens, 2016, 12, e1005636.	4.7	84
58	Nomenclature- and Database-Compatible Names for the Two Ebola Virus Variants that Emerged in Guinea and the Democratic Republic of the Congo in 2014. Viruses, 2014, 6, 4760-4799.	3.3	83
59	Amplification of Full-Length Hepatitis B Virus Genomes from Samples from Patients with Low Levels of Viremia: Frequency and Functional Consequences of PCR-Introduced Mutations. Journal of Clinical Microbiology, 1998, 36, 531-538.	3.9	83
60	Inhibition of Different Lassa Virus Strains by Alpha and Gamma Interferons and Comparison with a Less Pathogenic Arenavirus. Journal of Virology, 2004, 78, 3162-3169.	3.4	81
61	New Lineage of Lassa Virus, Togo, 2016. Emerging Infectious Diseases, 2018, 24, 599-602.	4.3	79
62	Naturally Occurring Hepatitis B Virus Genomes Bearing the Hallmarks of Retroviral G â†' A Hypermutation. Virology, 1997, 235, 104-108.	2.4	77
63	Complex HBV populations with mutations in core promoter, C gene, and pre-S region are associated with development of cirrhosis in long-term renal transplant recipients. Hepatology, 2002, 35, 466-477.	7.3	77
64	Sequence and phylogenetic analysis of hepatitis B virus genotype G isolated in Germany. Virus Genes, 2002, 24, 153-156.	1.6	72
65	Containing a Lassa fever epidemic in a resource-limited setting: outbreak description and lessons learned from Abakaliki, Nigeria (January–March 2012). International Journal of Infectious Diseases, 2013, 17, e1011-e1016.	3.3	72
66	Novel Arenavirus Sequences in Hylomyscus sp. and Mus (Nannomys) setulosus from CÃ'te d'Ivoire: Implications for Evolution of Arenaviruses in Africa. PLoS ONE, 2011, 6, e20893.	2.5	72
67	Ebola Virus Persistence in Breast Milk After No Reported Illness: A Likely Source of Virus Transmission From Mother to Child. Clinical Infectious Diseases, 2016, 64, ciw793.	5.8	70
68	Current Molecular Epidemiology of Lassa Virus in Nigeria. Journal of Clinical Microbiology, 2011, 49, 1157-1161.	3.9	68
69	Viral metagenomics, genetic and evolutionary characteristics of Crimean-Congo hemorrhagic fever orthonairovirus in humans, Kosovo. Infection, Genetics and Evolution, 2018, 65, 6-11.	2.3	66
70	ICTV Virus Taxonomy Profile: Arenaviridae. Journal of General Virology, 2019, 100, 1200-1201.	2.9	66
71	Detection of Usutu virus infection in a healthy blood donor from south-west Germany, 2012. Eurosurveillance, 2012, 17, .	7.0	66
72	Diagnostic Reverseâ€Transcription Polymerase Chain Reaction Kit for Filoviruses Based on the Strain Collections of all European Biosafety Level 4 Laboratories. Journal of Infectious Diseases, 2007, 196, S199-S204.	4.0	65

#	Article	IF	Citations
73	Hepatitis B virus sequence changes evolving in liver transplant recipients with fulminant hepatitis. Journal of Hepatology, 1997, 26, 754-764.	3.7	63
74	Health Care Response to CCHF in US Soldier and Nosocomial Transmission to Health Care Providers, Germany, 2009. Emerging Infectious Diseases, 2015, 21, 23-31.	4.3	62
75	2021 Taxonomic update of phylum Negarnaviricota (Riboviria: Orthornavirae), including the large orders Bunyavirales and Mononegavirales. Archives of Virology, 2021, 166, 3513-3566.	2.1	62
76	Lassa Fever. Infectious Disease Clinics of North America, 2019, 33, 933-951.	5.1	61
77	Accumulation and persistence of hepatitis B virus core gene deletion mutants in renal transplant patients are associated with end-stage liver disease. Hepatology, 1996, 24, 751-758.	7.3	59
78	Ebola virus dynamics in mice treated with favipiravir. Antiviral Research, 2015, 123, 70-77.	4.1	57
79	Functional analysis of HBV genomes from patients with fulminant hepatitis. Hepatology, 1998, 28, 1390-1397.	7.3	56
80	Dilemmas in Managing Pregnant Women With Ebola: 2 Case Reports: Table 1 Clinical Infectious Diseases, 2016, 62, 903-905.	5.8	56
81	Depletion of GTP pool is not the predominant mechanism by which ribavirin exerts its antiviral effect on Lassa virus. Antiviral Research, 2011, 91, 89-93.	4.1	55
82	Application of real-time PCR for testing antiviral compounds against Lassa virus, SARS coronavirus and Ebola virus in vitro. Antiviral Research, 2004, 63, 209-215.	4.1	54
83	Mopeia Virus–related Arenavirus in Natal Multimammate Mice <i>&gt;,</i> i>Morogoro, Tanzania. Emerging Infectious Diseases, 2009, 15, 2008-2012.	4.3	54
84	An N-Terminal Region of Lassa Virus L Protein Plays a Critical Role in Transcription but Not Replication of the Virus Genome. Journal of Virology, 2010, 84, 1934-1944.	3.4	53
85	Lassa Serology in Natural Populations of Rodents and Horizontal Transmission. Vector-Borne and Zoonotic Diseases, 2014, 14, 665-674.	1.5	52
86	Hepatitis B virus variants with core gene deletions in the evolution of chronic hepatitis B infection. Gastroenterology, 1996, 111, 183-192.	1.3	49
87	Phylogeography of Lassa Virus in Nigeria. Journal of Virology, 2019, 93, .	3.4	49
88	Interferon $\hat{I}^2$ -1a for the treatment of Ebola virus disease: A historically controlled, single-arm proof-of-concept trial. PLoS ONE, 2017, 12, e0169255.	2.5	48
89	First International Quality Assurance Study on the Rapid Detection of Viral Agents of Bioterrorism. Journal of Clinical Microbiology, 2004, 42, 1753-1755.	3.9	47
90	Structure of the Lassa Virus Nucleoprotein Revealed by X-ray Crystallography, Small-angle X-ray Scattering, and Electron Microscopy. Journal of Biological Chemistry, 2011, 286, 38748-38756.	3.4	47

#	Article	IF	Citations
91	Different features of $\hat{V}$ 12 T and NK cells in fatal and non-fatal human Ebola infections. PLoS Neglected Tropical Diseases, 2017, 11, e0005645.	3.0	46
92	Safety, reactogenicity, and immunogenicity of a chimpanzee adenovirus vectored Ebola vaccine in adults in Africa: a randomised, observer-blind, placebo-controlled, phase 2 trial. Lancet Infectious Diseases, The, 2020, 20, 707-718.	9.1	45
93	Mutational Analysis of the Lassa Virus Promoter. Journal of Virology, 2006, 80, 12414-12419.	3.4	44
94	Presence of Mopeia Virus, an African Arenavirus, Related to Biotope and Individual Rodent Host Characteristics: Implications for Virus Transmission. Vector-Borne and Zoonotic Diseases, 2011, 11, 1125-1131.	1.5	44
95	Infection of Type I Interferon Receptor-Deficient Mice with Various Old World Arenaviruses: A Model for Studying Virulence and Host Species Barriers. PLoS ONE, 2013, 8, e72290.	2.5	44
96	Structural and functional characterization of the severe fever with thrombocytopenia syndrome virus L protein. Nucleic Acids Research, 2020, 48, 5749-5765.	14.5	44
97	Neonatal Fulminant Hepatitis B: Structural and Functional Analysis of Complete Hepatitis B Virus Genomes from Mother and Infant. Journal of Infectious Diseases, 1998, 177, 1378-1381.	4.0	42
98	Genetic variation in HBV infection: genotypes and mutants. Journal of Clinical Virology, 2006, 36, S3-S11.	3.1	41
99	High Diversity of RNA Viruses in Rodents, Ethiopia. Emerging Infectious Diseases, 2012, 18, 2047-2050.	4.3	41
100	Chimeric Mice with Competent Hematopoietic Immunity Reproduce Key Features of Severe Lassa Fever. PLoS Pathogens, 2016, 12, e1005656.	4.7	41
101	Widespread arenavirus occurrence and seroprevalence in small mammals, Nigeria. Parasites and Vectors, 2018, 11, 416.	2.5	41
102	Structure of a functional cap-binding domain in Rift Valley fever virus L protein. PLoS Pathogens, 2019, 15, e1007829.	4.7	41
103	Mutational Evidence for a Structural Model of the Lassa Virus RNA Polymerase Domain and Identification of Two Residues, Gly1394 and Asp1395, That Are Critical for Transcription but Not Replication of the Genome. Journal of Virology, 2008, 82, 10207-10217.	3.4	40
104	Functional Analysis of Complex Hepatitis B Virus Variants Associated With Development of Liver Cirrhosis. Gastroenterology, 2006, 131, 765-780.	1.3	39
105	Laboratory Findings, Compassionate Use of Favipiravir, and Outcome in Patients With Ebola Virus Disease, Guinea, 2015—A Retrospective Observational Study. Journal of Infectious Diseases, 2019, 220, 195-202.	4.0	38
106	Shedding dynamics of Morogoro virus, an African arenavirus closely related to Lassa virus, in its natural reservoir host Mastomys natalensis. Scientific Reports, 2015, 5, 10445.	3.3	37
107	Sensitive and specific detection of Crimean-Congo Hemorrhagic Fever Virus (CCHFV)—Specific IgM and IgG antibodies in human sera using recombinant CCHFV nucleoprotein as antigen in μ-capture and IgG immune complex (IC) ELISA tests. PLoS Neglected Tropical Diseases, 2018, 12, e0006366.	3.0	37
108	Analysis of Hepatitis B Virus Populations in an Interferon-α-Treated Patient Reveals Predominant Mutations in the C-Gene and Changing e-Antigenicity. Virology, 1998, 244, 146-160.	2.4	36

#	Article	lF	CITATIONS
109	Prevalence of hepatitis B virus DNA in anti-HBc-positive/HBsAg-negative sera correlates with HCV but not HIV serostatus. Journal of Clinical Virology, 2004, 29, 59-68.	3.1	36
110	Complete sequence and phylogenetic characterisation of Crimean–Congo hemorrhagic fever virus from Afghanistan. Journal of Clinical Virology, 2011, 50, 90-92.	3.1	36
111	Ebola Virus Disease in Mice with Transplanted Human Hematopoietic Stem Cells. Journal of Virology, 2015, 89, 4700-4704.	3.4	36
112	Arenavirus Diversity and Phylogeography of <i>Mastomys natalensis </i> Rodents, Nigeria. Emerging Infectious Diseases, 2016, 22, 687-690.	4.3	36
113	Determining Ribavirin's mechanism of action against Lassa virus infection. Scientific Reports, 2017, 7, 11693.	3.3	36
114	Evaluation of rodent control to fight Lassa fever based on field data and mathematical modelling. Emerging Microbes and Infections, 2019, 8, 640-649.	6.5	36
115	Research efforts to control highly pathogenic arenaviruses: A summary of the progress and gaps. Journal of Clinical Virology, 2015, 64, 120-127.	3.1	35
116	Biochemical characterization of the Lassa virus L protein. Journal of Biological Chemistry, 2019, 294, 8088-8100.	3.4	35
117	Hepatitis B virus genomes from long-term immunosuppressed virus carriers are modified by specific mutations in several regions. Journal of General Virology, 1999, 80, 2685-2691.	2.9	35
118	Enhanced Replication Contributes to Enrichment of Hepatitis B Virus with a Deletion in the Core Gene. Virology, 2000, 273, 286-299.	2.4	34
119	Gairo virus, a novel arenavirus of the widespread Mastomys natalensis: Genetically divergent, but ecologically similar to Lassa and Morogoro viruses. Virology, 2015, 476, 249-256.	2.4	34
120	Caseload and Case Fatality of Lassa Fever in Nigeria, 2001–2018: A Specialist Center's Experience and Its Implications. Frontiers in Public Health, 2019, 7, 170.	2.7	34
121	Retrospective Cohort Study of Lassa Fever in Pregnancy, Southern Nigeria. Emerging Infectious Diseases, 2019, 25, 1494-1500.	4.3	34
122	Reverse ELISA for IgG and IgM antibodies to detect Lassa virus infections in Africa. Journal of Clinical Virology, 2006, 37, 277-281.	3.1	33
123	Strain-specific antibody response to Lassa virus in the local population of west Africa. Journal of Clinical Virology, 2008, 42, 40-44.	3.1	33
124	Sympatric Occurrence of 3 Arenaviruses, Tanzania. Emerging Infectious Diseases, 2010, 16, 692-695.	4.3	33
125	Evaluation of RealStar Reverse Transcriptionâ€"Polymerase Chain Reaction Kits for Filovirus Detection in the Laboratory and Field. Journal of Infectious Diseases, 2016, 214, S243-S249.	4.0	33
126	International External Quality Assessment Study for Molecular Detection of Lassa Virus. PLoS Neglected Tropical Diseases, 2015, 9, e0003793.	3.0	32

#	Article	IF	CITATIONS
127	Analysis of Diagnostic Findings From the European Mobile Laboratory in Guéckédou, Guinea, March 2014 Through March 2015. Journal of Infectious Diseases, 2016, 214, S250-S257.	4.0	32
128	Structural insights into reptarenavirus cap-snatching machinery. PLoS Pathogens, 2017, 13, e1006400.	4.7	32
129	Prevalence of Lassa Virus Disease (LVD) in Nigerian children with fever or fever and convulsions in an endemic area. PLoS Neglected Tropical Diseases, 2017, 11, e0005711.	3.0	32
130	Ebola Virus Disease Is Characterized by Poor Activation and Reduced Levels of Circulating CD16 <sup>+</sup> Monocytes. Journal of Infectious Diseases, 2016, 214, S275-S280.	4.0	31
131	Ebola virus infection kinetics in chimeric mice reveal a key role of T cells as barriers for virus dissemination. Scientific Reports, 2017, 7, 43776.	3.3	31
132	Biochemical and structural studies reveal differences and commonalities among cap-snatching endonucleases from segmented negative-strand RNA viruses. Journal of Biological Chemistry, 2018, 293, 19686-19698.	3.4	31
133	Atomic Structure and Biochemical Characterization of an RNA Endonuclease in the N Terminus of Andes Virus L Protein. PLoS Pathogens, 2016, 12, e1005635.	4.7	31
134	Domain Structure of Lassa Virus L Protein. Journal of Virology, 2011, 85, 324-333.	3.4	30
135	Pathogenicity Comparison Between the Kikwit and Makona Ebola Virus Variants in Rhesus Macaques. Journal of Infectious Diseases, 2016, 214, S281-S289.	4.0	30
136	Deep Sequencing of RNA from Blood and Oral Swab Samples Reveals the Presence of Nucleic Acid from a Number of Pathogens in Patients with Acute Ebola Virus Disease and Is Consistent with Bacterial Translocation across the Gut. MSphere, 2017, 2, .	2.9	30
137	The European Virus Archive goes global: A growing resource for research. Antiviral Research, 2018, 158, 127-134.	4.1	30
138	Lassa fever outcomes and prognostic factors in Nigeria (LASCOPE): a prospective cohort study. The Lancet Global Health, 2021, 9, e469-e478.	6.3	30
139	Broad-Spectrum Antiviral Activity of Small Interfering RNA Targeting the Conserved RNA Termini of Lassa Virus. Antimicrobial Agents and Chemotherapy, 2007, 51, 2215-2218.	3.2	29
140	Cross-Species Analysis of the Replication Complex of Old World Arenaviruses Reveals Two Nucleoprotein Sites Involved in L Protein Function. Journal of Virology, 2011, 85, 12518-12528.	3.4	29
141	Spatial and temporal evolution of Lassa virus in the natural host population in Upper Guinea. Scientific Reports, 2016, 6, 21977.	3.3	28
142	Control measures following a case of imported Lassa fever from Togo, North Rhine Westphalia, Germany, 2016. Eurosurveillance, 2017, 22, .	7.0	28
143	Role of the C Terminus of Lassa Virus L Protein in Viral mRNA Synthesis. Journal of Virology, 2014, 88, 8713-8717.	3.4	27
144	Longitudinal antibody and T cell responses in Ebola virus disease survivors and contacts: an observational cohort study. Lancet Infectious Diseases, The, 2021, 21, 507-516.	9.1	26

#	Article	IF	Citations
145	Conformational changes in Lassa virus L protein associated with promoter binding and RNA synthesis activity. Nature Communications, 2021, 12, 7018.	12.8	26
146	Detection of Marburg Virus Disease in Guinea. New England Journal of Medicine, 2022, 386, 2528-2530.	27.0	26
147	Genetic Diversity and New Lineages of Dengue Virus Serotypes 3 and 4 in Returning Travelers, Germany, 2006–2015. Emerging Infectious Diseases, 2017, 23, 272-275.	4.3	25
148	T-Cell Receptor Diversity and the Control of T-Cell Homeostasis Mark Ebola Virus Disease Survival in Humans. Journal of Infectious Diseases, 2018, 218, S508-S518.	4.0	25
149	Kinetics of Soluble Mediators of the Host Response in Ebola Virus Disease. Journal of Infectious Diseases, 2018, 218, S496-S503.	4.0	25
150	Lassa Virus in Pygmy Mice, Benin, 2016–2017. Emerging Infectious Diseases, 2019, 25, 1977-1979.	4.3	25
151	Hospital-Based Surveillance for Viral Hemorrhagic Fevers and Hepatitides in Ghana. PLoS Neglected Tropical Diseases, 2013, 7, e2435.	3.0	24
152	Analysis of gene expression in Lassa virus-infected HuH-7 cells. Journal of General Virology, 2007, 88, 1568-1575.	2.9	24
153	Seroepidemiological study reveals regional coâ€occurrence of <scp>L</scp> assa―and <scp>H</scp> antavirus antibodies in <scp>U</scp> pper <scp>G</scp> uinea, <scp>W</scp> est <scp>A</scp> frica. Tropical Medicine and International Health, 2013, 18, 366-371.	2.3	23
154	Lassa fever in Benin: description of the 2014 and 2016 epidemics and genetic characterization of a new Lassa virus. Emerging Microbes and Infections, 2020, 9, 1761-1770.	6.5	23
155	Heterogeneity of hepatitis B virus C-gene sequences: Implications for amplification and sequencing. Journal of Hepatology, 1993, 18, 53-61.	3.7	22
156	The European network of Biosafety-Level-4 laboratories: enhancing European preparedness for new health threats. Clinical Microbiology and Infection, 2009, 15, 720-726.	6.0	22
157	Diketo acids inhibit the cap-snatching endonuclease of several Bunyavirales. Antiviral Research, 2020, 183, 104947.	4.1	22
158	Clinical Management of Argentine Hemorrhagic Fever using Ribavirin and Favipiravir, Belgium, 2020. Emerging Infectious Diseases, 2020, 26, 1562-1566.	4.3	21
159	Structural and functional heterogeneity of naturally occurring hepatitis B virus variants. Antiviral Research, 2001, 52, 125-138.	4.1	20
160	Laboratory Diagnosis of Lassa Fever, Liberia. Emerging Infectious Diseases, 2010, 16, 1041-1043.	4.3	20
161	No measurable adverse effects of Lassa, Morogoro and Gairo arenaviruses on their rodent reservoir host in natural conditions. Parasites and Vectors, 2017, 10, 210.	2.5	20
162	Modeling Favipiravir Antiviral Efficacy Against Emerging Viruses: From Animal Studies to Clinical Trials. CPT: Pharmacometrics and Systems Pharmacology, 2020, 9, 258-271.	2.5	20

#	Article	IF	CITATIONS
163	Households as hotspots of Lassa fever? Assessing the spatial distribution of Lassa virus-infected rodents in rural villages of Guinea. Emerging Microbes and Infections, 2020, 9, 1055-1064.	6.5	20
164	Familial clustering of HBV pre-C and pre-S mutants. Journal of Hepatology, 1997, 26, 221-227.	3.7	19
165	Small mammal diversity and dynamics within Nigeria, with emphasis on reservoirs of the lassa virus. Systematics and Biodiversity, 2018, 16, 118-127.	1.2	19
166	Development and evaluation of antibody-capture immunoassays for detection of Lassa virus nucleoprotein-specific immunoglobulin M and G. PLoS Neglected Tropical Diseases, 2018, 12, e0006361.	3.0	18
167	Variation around the dominant viral genome sequence contributes to viral load and outcome in patients with Ebola virus disease. Genome Biology, 2020, 21, 238.	8.8	18
168	Antibodies to Lassa virus Z protein and nucleoprotein co-occur in human sera from Lassa fever endemic regions. Medical Microbiology and Immunology, 2001, 189, 225-229.	4.8	17
169	The N Terminus of Andes Virus L Protein Suppresses mRNA and Protein Expression in Mammalian Cells. Journal of Virology, 2013, 87, 6975-6985.	3.4	17
170	Heterologous arenavirus vector prime-boost overrules self-tolerance for efficient tumor-specific CD8 TÂcell attack. Cell Reports Medicine, 2021, 2, 100209.	6.5	16
171	Arenavirus infection correlates with lower survival of its natural rodent host in a long-term capture-mark-recapture study. Parasites and Vectors, 2018, 11, 90.	2.5	15
172	Crimean-Congo Hemorrhagic Fever, Kosovo, 2013–2016. Emerging Infectious Diseases, 2019, 25, 321-324.	4.3	15
173	Severe Human Lassa Fever Is Characterized by Nonspecific T-Cell Activation and Lymphocyte Homing to Inflamed Tissues. Journal of Virology, 2020, 94, .	3.4	14
174	Field evaluation of a Pan-Lassa rapid diagnostic test during the 2018 Nigerian Lassa fever outbreak. Scientific Reports, 2020, 10, 8724.	3.3	14
175	Density dependence and persistence of Morogoro arenavirus transmission in a fluctuating population of its reservoir host. Journal of Animal Ecology, 2020, 89, 506-518.	2.8	13
176	Ebola Virus Disease Survivors Show More Efficient Antibody Immunity than Vaccinees Despite Similar Levels of Circulating Immunoglobulins. Viruses, 2020, 12, 915.	3.3	13
177	Experimental Morogoro Virus Infection in Its Natural Host, Mastomys natalensis. Viruses, 2021, 13, 851.	3.3	13
178	Rift Valley fever virus minigenome system for investigating the role of L protein residues in viral transcription and replication. Journal of General Virology, 2019, 100, 1093-1098.	2.9	13
179	External quality assessment study for ebolavirus PCR-diagnostic promotes international preparedness during the 2014 – 2016 Ebola outbreak in West Africa. PLoS Neglected Tropical Diseases, 2017, 11, e0005570.	3.0	13
180	Virus persistence after recovery from acute Lassa fever in Nigeria: a 2-year interim analysis of a prospective longitudinal cohort study. Lancet Microbe, The, 2022, 3, e32-e40.	7.3	13

#	Article	IF	Citations
181	A New Class of Defective Hepatitis B Virus Genomes with an Internal Poly(dA) Sequence. Virology, 1997, 239, 402-412.	2.4	12
182	Early serodiagnosis of acute human Crimean-Congo hemorrhagic fever virus infections by novel capture assays. Journal of Clinical Virology, 2010, 48, 294-295.	3.1	12
183	Increased Proinflammatory Cytokine Levels in Prolonged Arthralgia in Ross River Virus Infection. Emerging Infectious Diseases, 2017, 23, 702-704.	4.3	12
184	Acute Lassa Virus Encephalitis with Lassa Virus in the Cerebrospinal Fluid but Absent in the Blood: A Case Report with a Positive Outcome. Case Reports in Neurology, 2018, 10, 150-158.	0.7	12
185	Field investigation with real-time virus genetic characterisation support of a cluster of Ebola virus disease cases in Dubréka, Guinea, April to June 2015. Eurosurveillance, 2018, 23, .	7.0	11
186	Characterisation of the T-cell response to Ebola virus glycoprotein amongst survivors of the 2013–16 West Africa epidemic. Nature Communications, 2021, 12, 1153.	12.8	10
187	Metagenomic Snapshots of Viral Components in Guinean Bats. Microorganisms, 2021, 9, 599.	3.6	10
188	Co-replication analyses of naturally occurring defective hepatitis B virus variants with wild-type. Virology, 2008, 372, 247-259.	2.4	9
189	Human Diversity of Killer Cell Immunoglobulin-Like Receptors and Human Leukocyte Antigen Class I Alleles and Ebola Virus Disease Outcomes. Emerging Infectious Diseases, 2021, 27, 76-84.	4.3	8
190	Factors associated with progression to death in patients with Lassa fever in Nigeria: an observational study. Lancet Infectious Diseases, The, 2021, 21, 876-886.	9.1	8
191	Tigray Orthohantavirus Infects Two Related Rodent Species Adapted to Different Elevations in Ethiopia. Vector-Borne and Zoonotic Diseases, 2019, 19, 950-953.	1.5	7
192	Acute Abdomen in Pediatric Patients With Lassa Fever: Prevalence and Response to Nonoperative Management. Journal of the Pediatric Infectious Diseases Society, 2019, 8, 519-524.	1.3	7
193	A Sporadic and Lethal Lassa Fever Case in Forest Guinea, 2019. Viruses, 2020, 12, 1062.	3.3	7
194	Acute kidney injury and mortality in pediatric Lassa fever versus question of access to dialysis. International Journal of Infectious Diseases, 2021, 103, 124-131.	3.3	7
195	New lessons from a case series review of Lassa fever in pregnancy. International Journal of Infectious Diseases, 2010, 14, e380.	3.3	6
196	Cytokine Profile Distinguishes Children With Plasmodium falciparum Malaria From Those With Bacterial Blood Stream Infections. Journal of Infectious Diseases, 2020, 221, 1098-1106.	4.0	5
197	Enhanced efficacy of endonuclease inhibitor baloxavir acid against orthobunyaviruses when used in combination with ribavirin. Journal of Antimicrobial Chemotherapy, 2020, 75, 3189-3193.	3.0	5
198	Lassa fever clinical course and setting a standard of care for future randomized trials: A protocol for a cohort study of Lassa-infected patients in Nigeria (LASCOPE). Travel Medicine and Infectious Disease, 2020, 36, 101557.	3.0	5

#	Article	lF	CITATIONS
199	Validation of Inactivation Methods for Arenaviruses. Viruses, 2021, 13, 968.	3.3	5
200	Naturally occurring mutations of hepatitis B virus and outcome of chronic infection: Is there an association?. European Journal of Clinical Investigation, 2000, 30, 751-753.	3.4	4
201	Crimean congo hemorrhagic fever, 2013 and 2014 Sudan. International Journal of Infectious Diseases, 2016, 53, 9.	3.3	4
202	Prospective observational study on the pharmacokinetic properties of the Irrua ribavirin regimen used in routine clinical practice in patients with Lassa fever in Nigeria. BMJ Open, 2020, 10, e036936.	1.9	4
203	Human Dobrava-Belgrade hantavirus infection, Kosovo. Journal of Clinical Virology, 2014, 61, 439-441.	3.1	3
204	G311â€Lassa fever and convulsions associated with fever: A case-control study. , 2017, , .		1
205	Evaluating case definitions for Ebola virus disease. Lancet Infectious Diseases, The, 2020, 20, 1224-1226.	9.1	1
206	Detection of Lassa Virus-Reactive IgG Antibodies in Wild Rodents: Validation of a Capture Enzyme-Linked Immunological Assay. Viruses, 2022, 14, 993.	3.3	1
207	A40â€fEstimation of Lassa virus emergence in Upper Guinea through a time-calibrated phylogeny. Virus Evolution, 2019, 5, .	4.9	0